What factors affect a sufficient dose of phenofibrate?

Since its reformulation as a medical Tricor® in 2005, fenofibrate was used mainly in patients with a danger of serious cardiovascular risk to reduce low density lipoprotein (LDL), known as bad cholesterol, as well as increase lipoprotein with high density (HDL) known as good cholesterol. Unfortunately, the conclusion of the massive longitudinal fenofibrate of intervention and reducing events in the Diabetes study surprisingly did not detect any statistically significant reduction in the risk of heart attack or coronary heart disease Death, whether the drug was used with statin drugs. However, the study has found a significant reduction in the occurrence of some types of amputations in diabetic patients, although its efficacy is probably due to non -illiced ​​mechanisms. Other use of fenofibrate is additional DNA treatment or as an alternative drug for blood glitter. When used for these purposes and also in patients with less renal impairment, lower fem can be used a dose of nofibrates.

While patients with CRCL level less than 50 ml/min, or less than 30 ml/min in the case of Fenoglide®, are considered to be too severe renal insufficiency to take this medicine, patients with levels between 80 ml/min and 50 ml/min, or 80 ml/min and 30 ml/min for fenoglide. According to the manufacturer's recommendation, the daily dose of fenofibrates in patients taking Lofibra® who have less reduced kidney function, 67 mg once daily with food, while the recommended dose for patients taking Antara® is 43 mg. TRIGLIDE® patients should have 50 mg of food doses a day, while those who qualify for Fenoglide® should take one 40 mg dose. The dose of fenofibrates should only be increased after careful consideration of the effects of the drug on the level of lipids and the kidney function.

Production for adult patients under 65 years of age with normal kidney function that was diagnosed with high blood cholesterol and IIB blood, NazThey load one fenofibrate dose of 145 mg in the form of Tricor®, 130 mg as Antara®, 160 mg such as Triglide®, 150 mg as Lipofen® and 120 mg ° C. In the treatment of cholesterol with high blood type IV and V, the only fenofibrate between 48 mg and 145 mg in the form of TRICOR®, 43 mg and 130 and 130 MG such as Antara®, 50 mg and 160 mg such as Triglide®, 50 mg and 150 mg like Lipofen® and 40 mg to 120 mg. The dose can be adjusted according to the patient's reaction as necessary when evaluating every four to eight weeks.

Patients over 65 years of age should use lower fenofibrate dosage than in adults under 65 years due to its possible effects on the kidney function. Initially, the lowest recommended dose in patients with cholesterol with high blood and type V blood should be followed by all geriatric patients. The dose can be increased every four to eight weeks if accompanied by careful monitoring of the kidney function and blood fenofibrate levels.